Cytospire's novel pan-gamma T cell engagers offer a compelling solution to the efficacy and safety challenges faced by conventional T cell engagers
New financing will accelerate Cytospire's pipeline in solid and liquid tumours, including advancement of lead program, CYT X300 targeting EGFR-positive cancers, to clinical proof-of-concept
Secures the first-ever investment from Servier's newly formed corporate venture fund
London, UK – May 05, 2026. Cytospire Therapeutics (‘Cytospire'), a UK based biotech developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body's own immune system, today announces the closing of an oversubscribed £61 million ($83 million) Series A financing supported by a strong syndicate of new and existing biotech investors.
Cytospire will use the proceeds to advance its pipeline of first-in-class pan-gamma delta T cell engagers, including its lead programme, CYT X300, which is currently being advanced through IND-enabling preclinical studies and GMP manufacturing. A first-in-human clinical study is being planned to evaluate CYT X300 as a treatment for EGFR-positive solid tumours, such as colorectal, head and neck and non-small cell lung cancers.
The round was led by 4BIO Capital, with significant investment from new syndicate members Servier Ventures, British Business Bank, Sound Bioventures and Criteria Bio Ventures, as well as from existing investors Abingworth ...
